Five New Infectious Disease Control Panels Released Worldwide

The panels can be used with most instrument platforms and test methods.

The new infectious disease panels were launched by SeraCare Life Sciences (Milford, MA, USA), a provider of human biologicals for supporting diagnostics, research, and therapeutics.

They are vital for assay development and regulatory compliance and provide a common reference for assay comparison and troubleshooting of existing assays.

Parvovirus B19 mixed titer performance panel (PVP201) was designed to help diagnostic manufacturers, clinical laboratories, and plasma fractionators evaluate their parvovirus assays. The panel contains 21 samples characterized for multiple immunoglobulin M (IgM) and IgG assays as well as B19 DNA, a marker used to screen plasma collected for fractionation.

The HIV genotype performance panel (PRD201) provides a diverse set of samples, both geographically and in terms of genotypes: eight of the nine panel members are HIV positive, representing eight different HIV-1 genotypes from seven countries.

Worldwide HBV DNA performance panel (WWHD301) marks the addition of a worldwide Hepatitis B panel to SeraCare’s panel offerings. The 20-member panel includes samples from 10 countries with HBV genotypes ranging from A through H. The broad range of data provides information on genotype, drug resistance mutations, and test results for HBV DNA, HBsAg and HBeAg

Anti-Hepatitis A Virus mixed titer performance panel (PHT202) offers a 21-member panel that includes members positive for IgG and IgM, and represents a diverse range of HAV reactivities (from low to medium to high). The range of data includes information on genotype, drug resistance mutations, and test results for HBV DNA, HBsAg and HBeAg

The Anti-CMV (Cytomegalovirus) mixed titer performance panel (PTC203) provides 21 naturally occurring panel members with data from twelve commercially available anti-CMV assays. It also features a detailed graphical representation of test member results, making it easier to find and utilize relevant data.

Chris Long, associate product manager at SeraCare Life Sciences, said, “Our decision to develop the first performance panel for parvovirus B19 was fueled by the recent release of two new clinical test platforms for B19 DNA, with more currently under development by leading manufacturers. Our ability to identify, develop and release new products efficiently helps to get rare and valuable validation and control materials into our customers’ hands so they can get their new assays up and running.”

Related Links:
SeraCare Life Sciences